Chinese University of Hong Kong

BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW

Retrieved on: 
Thursday, April 13, 2023
SAB, DNA, Lasker-DeBakey Clinical Medical Research Award, AACR, Cell biology, Methylation, Applied Biosystems, Genetics, Workflow, Neurodegenerative disease, Liquid biopsy, Cancer, American Association for Cancer Research, Coronavirus Scientific Advisory Board, Research, Biomarker, Chinese University of Hong Kong, Nasopharyngeal carcinoma, Cytosine, Chinese, Blood, Reading, Outline of health sciences, Biology, CUHK, Peter MacCallum Cancer Centre, Neoplasm, Health, Genome, The central science, Disease, Medical imaging, Pharmaceutical industry, Management, Computer data storage, Vaccine, Medicine, Nature Biotechnology

CAMBRIDGE, England, April 13, 2023 /PRNewswire/ -- The duet multiomics solution is the world's first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a single sample, with one workflow, using any sequencer. The hardware-agnostic product provides more epigenetic information from a single low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Recently published in Nature Biotechnology, the solution provides a more complete picture of the information stored in genomes availing new insights from applications throughout biomedicine.

Key Points: 
  • "Our novel solution removes the technical barriers that have previously held back our broader understanding of epigenetics.
  • Now, our customers can accelerate their research with a more comprehensive view of regulatory function across the genome, through the interplay of genetics and epigenetics at read level.
  • The duet multiomics solution empowers applications across numerous fields of disease research, delivering greater biological insights into cancer, neurodegenerative disease, ageing, cell biology and population genetics.
  • Using cell-free DNA via liquid biopsy, duet multiomics can simultaneously detect powerful genetic and methylation biomarkers in an individual's blood to provide unique disease insights.

FINTOCH Wins Top 10 Web3 Technology Innovation Award at the World WEB3 Summit

Retrieved on: 
Wednesday, March 29, 2023
Convention center, Huawei, Chinese University of Hong Kong, Government, Congress, Chinese, FTC, OKX, Tutoring, Film industry, Metaverse

Hong Kong, Hong Kong--(Newsfile Corp. - March 28, 2023) - FINTOCH received recognition as one of the world's top ten Web3 technology innovators at the recent World WEB3 Summit in Hong Kong.

Key Points: 
  • Hong Kong, Hong Kong--(Newsfile Corp. - March 28, 2023) - FINTOCH received recognition as one of the world's top ten Web3 technology innovators at the recent World WEB3 Summit in Hong Kong.
  • The summit attracted government officials and industry leaders from around the world, including from Tron, Huawei, the Chinese University of Hong Kong, OKX, and FINTOCH.
  • The company's innovative technology has previously recognised at the North American Blockchain Summit and has now won the "Top 10 Web3 Technology Innovation Award" at the World WEB3 Summit, highlighting the company's impact on the industry.
  • Industry insiders noted that while this is not the first time that FINTOCH has won an award for its technology, its recognition at the World WEB3 Summit in Hong Kong underlines the company's influence in the Asia-Pacific region.

Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery

Retrieved on: 
Tuesday, March 21, 2023
Asset purchase agreement, WESA, LLP, CSE, Committee, Special, MBA, Research, Sale, Chinese University of Hong Kong, WHI, Circular, US, Chinese, DSM-IV codes, Proxy, Transaction, Corporation, SEDAR, Capital, CFO, Growth, Report of the Special Committee on the Termination of the National Emergency, McCarthy, US FDA, Holding company, Car rental, Pharmaceutical industry, Lease, Security (finance), Management, Audit

The Company will also have economic exposure to the broader Lucy asset portfolio and pipeline, including a Canadian Licensed Dealer conducting research on various compounds.

Key Points: 
  • The Company will also have economic exposure to the broader Lucy asset portfolio and pipeline, including a Canadian Licensed Dealer conducting research on various compounds.
  • The Asset Purchase Agreement also contains customary non-solicitation covenants on the part of Wesana with respect to alternative transactions.
  • Accordingly, the Board has approved the Asset Purchase Agreement and recommends that Wesana shareholders vote in favour of the Transaction.
  • Eight Capital is acting as financial advisor, and Nauth LPC and McCarthy Tétrault LLP are acting as legal counsel to Wesana.

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology

Retrieved on: 
Tuesday, March 14, 2023
ACT, AstraZeneca, Cancer, Acquisition, United Kingdom, Workforce, Medicine, Chairperson, Genomics, Chinese University of Hong Kong, Chinese, Patient, Nature, Investment, EBITDA, COVID-19, FDA, Communication, Growth, Coronavirus Scientific Advisory Board, Social responsibility, Cryptocurrency, Pharmaceutical industry, Medical imaging, Vaccine, Renewable energy, Video game, Insurance, Bank, Artisan

-- Cash and other short-term assets of US$242.1 million as of December 31, 2022

Key Points: 
  • -- Cash and other short-term assets of US$242.1 million as of December 31, 2022
    -- Embarked on a new business strategy focused on precision oncology, as the Company exits the COVID-19 testing business.
  • Furthermore, I am immensely optimistic with our new business strategy in precision oncology.
  • Prenetics is focusing its business strategy to genomics and precision oncology, and is dedicated to transforming patients' care through advanced genomic and molecular technologies.
  • -- Adjusted EBITDA was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 14, 2023
ACT, AstraZeneca, Cancer, Acquisition, United Kingdom, Workforce, Medicine, Chairperson, Depreciation, Genomics, Chinese University of Hong Kong, Chinese, Nature, Investment, EBITDA, COVID-19, FDA, Communication, Growth, Coronavirus Scientific Advisory Board, Social responsibility, Cryptocurrency, Bank, Pharmaceutical industry, Medical imaging, Vaccine, Renewable energy, Video game, Insurance, Artisan

Revenue was US$52.3 million for the fourth quarter 2022 compared to US$64.7 million for the fourth quarter 2021, a decrease of 19.2% year-over-year.

Key Points: 
  • Revenue was US$52.3 million for the fourth quarter 2022 compared to US$64.7 million for the fourth quarter 2021, a decrease of 19.2% year-over-year.
  • Gross margin was 51.6% for the fourth quarter 2022 compared to 36.7% for the fourth quarter 2021.
  • Profit from operations was US$4.6 million for the fourth quarter 2022 compared to loss from operations of US$30.8 million for the fourth quarter 2021.
  • Adjusted EBITDA3 was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.

Appointment of Assistant Privacy Commissioner for Personal Data

Retrieved on: 
Sunday, February 26, 2023
Privacy, Technology, Communication, Equal Opportunities Commission (Hong Kong), University, Privacy Commissioner, Strategic management, Ombudsman, Leadership, Complaint, Partner, Board, Media studies, Graduate diploma, United Kingdom, College, Education, Television and Entertainment Licensing Authority, Culture, Exercise, British Board of Film Classification, Entertainment, Chinese, Language, Committee, Chinese University of Hong Kong, Television, Public sector, Literature, Equal Opportunities Commission, Office of the Ombudsman (Hong Kong), Classification, Personal data, Management

Date: 12 March 2018

Key Points: 
  • Date: 12 March 2018
    Appointment of Assistant Privacy Commissioner for Personal Data
    (12 March 2018) The Privacy Commissioner for Personal Data, Hong Kong (Privacy Commissioner) Mr Stephen Kai-yi WONG is pleased to announce, following an open recruitment exercise, the appointment of Mr Eric TSE as the Assistant Privacy Commissioner for Personal Data (Complaints, Communications & Education) with effect from 5 March 2018.
  • Mr Tse has over 25 years of management and regulatory experience in the public sector and had served in numerous public organisations in Hong Kong and in the United Kingdom.
  • Before joining the office of the Privacy Commissioner for Personal Data (PCPD), Mr Tse had served in the Office of The Ombudsman for 12 years.
  • The recruitment exercise was conducted by a selection board which comprised the Privacy Commissioner Mr Stephen Kai-yi WONG, Ms Cordelia CHUNG (Managing Director, Corporate Strategy, Asia, LIXIL Corporation; member of the PCPD's Personal Data (Privacy) Advisory Committee) and Mr Mark PARSONS (Partner, Hogan Lovells; member of the PCPD's Standing Committee on Technological Development).

HKTDC: Creativity showcase raises curtain on jewellery shows

Retrieved on: 
Friday, February 24, 2023
Diamond, Yee, Blockchain, Hong Kong Trade Development Council Trade Fairs, Dartmouth College student groups, Technique, Introduction, Culture, Human, Water, National Council for Technological Awards, Judo at the 1984 Summer Olympics – Men's open category, Themed Entertainment Association, Chow Tai Fook, Hong, Silver, Water resources, Convention center, World tree, Tin, Dolphin, Beetle, Student, Metal, Creativity, HKTDC, World Tree (role-playing game), The Open Group, Creation, Research, Chinese University of Hong Kong, Seed, Growth, NFT, Soil, Goldsmith, Abiogenesis, Second, Telenor, Bahr al-Hayat, Element, Consumer culture, Education, Alexander Oparin, Wood, Nature, Jewellery, Gemstone, In Utero, in Tribute, in Entirety, Life, Cyber City

As a curtain-raiser for the twin jewellery shows, the 24th Hong Kong Jewellery Design Competition was announced at the press conference (16 Feb).

Key Points: 
  • As a curtain-raiser for the twin jewellery shows, the 24th Hong Kong Jewellery Design Competition was announced at the press conference (16 Feb).
  • It promotes local jewellery design excellence, nurtures talent for the industry and showcases Hong Kong-made jewellery to international buyers.
  • Hong Kong design talents were encouraged to create and craft enthralling jewellery pieces based on culture, upbringing and life experiences.
  • From 1 to 5 March, more than 2,500 exhibitors will showcase exquisite jewellery items and raw materials at the Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show.

APRU Appoints Professor Thomas Schneider as New Chief Executive

Retrieved on: 
Thursday, February 2, 2023
Education, Other Education, Continuing, University, Central Steering Committee on Anti-corruption, Chinese University of Hong Kong, Pacific Alliance, Swiss National Science Foundation, APRU, Southern University of Science and Technology, University of Southern California, University of Zurich, Nazi Germany, Swansea University, National university, University of Auckland, International Secretariat for Volunteer Service, History, National University of Singapore, Student, Liberal arts college, Knowledge, Humanities, Associate, International, Secretariat, Multimedia, Near East, Search Committee, University of Basel, UCLA, Committee, STEM, Association of Pacific Rim Universities, Management, Nursing, Egyptology

The Association of Pacific Rim Universities (APRU) announced today that it had appointed Professor Thomas Schneider as its new Chief Executive, effective January 1, 2023.

Key Points: 
  • The Association of Pacific Rim Universities (APRU) announced today that it had appointed Professor Thomas Schneider as its new Chief Executive, effective January 1, 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230202005513/en/
    In announcing the appointment, APRU Chair and Chancellor of UCLA Professor Gene D. Block said, “Professor Schneider will bring considerable skills, knowledge, and experience to his new role, and I am confident that he has the ability to lead APRU into its next phase.
  • A native of Germany, Professor Schneider studied at the University of Zurich, the University of Basel, and the École Pratique des Hautes Études in Paris.
  • Professor Schneider was selected after an extensive global search by the APRU Search Committee led by Professor Rocky Tuan, Vice-Chair of APRU and Vice-Chancellor and President of The Chinese University of Hong Kong, and search partner Perrett Laver.

China's Guangdong stresses high-quality development at beginning of 2023

Retrieved on: 
Saturday, January 28, 2023
P&G, Chinese University of Hong Kong, Textile, National Development and Reform Commission, Software, United States Department of Commerce, Exhibition, Road, Employment, Government, Electronics, Food, GM, Belt and Road Initiative, Chinese New Year, Policy, Canton Fair, Growth, ExxonMobil, Information services, RCEP, Chinese, Car, Belt, Chemical, Daya Bay

"High-quality development is an inevitable path for Guangdong to achieve modernization.

Key Points: 
  • "High-quality development is an inevitable path for Guangdong to achieve modernization.
  • More specific policies and plans have been announced at the event, echoing the call on high-quality development.
  • Ai Xuefeng, Director General of Guangdong's Development and Reform Commission, said that in 2023, Guangdong has arranged 1530 provincial key projects with a total investment of 8.4 trillion RMB.
  • Guangdong has been known for its manufacturing industry worldwide with the industrial output exceeding 16 trillion RMB.

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

Retrieved on: 
Saturday, January 14, 2023
SAB, Development, Boston Scientific, TCT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, School, FDA, Research, Johnson & Johnson, Medical Affairs Bureau, Hope, Food, OTM, Medicine, Patient, Global Medical Device Nomenclature, Device, Physician, Chinese University of Hong Kong, European, Biomedical Advanced Research and Development Authority, Life, NIH, United States Air Force Scientific Advisory Board, Medical device

SHANGHAI, Jan. 14, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr. Mingdong Zhang to the company's Scientific Advisory Board (SAB).

Key Points: 
  • SHANGHAI, Jan. 14, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr. Mingdong Zhang to the company's Scientific Advisory Board (SAB).
  • Pulnovo Medical is a medical device company that focuses on innovative research and development, with the mission of meeting unmet clinical needs.
  • Dr. Zhang is an expert in medical device regulatory and corporate medical affairs with extensive medical knowledge and international regulatory affairs experience.
  • Pulnovo Medical added, "We are very grateful to have Dr. Mingdong Zhang on board to advise on our ongoing development of first-in-class original technologies.